drugset / Trial / NCT05377905

Microneedle Array Plus Doxorubicin in Cutaneous Squamous Cell Cancer (cSCC)

NCT05377905

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to test a new method of experimental treatment for cutaneous squamous cell skin cancer, using small adhesive-like patches (a micro-needle applicator or MNA for short), which have dozens of very small micro-needles loaded with extremely low doses of doxorubicin, a chemotherapy agent. The overall goal of this study is to test the safety and effectiveness of these patches. The investigators have established the highest tolerated dose at 50 micrograms in a previous study for a different type of cancer that affects the skin. The investigators will thoroughly evaluate the skin where the patches are applied.

Timeline

Start
2023-09-13
Primary completion
2027-03-31
Completion
2027-12-31

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Doxorubicin Other / unclassified 50 ug Topical